In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

References

• Abdallah, C., Besner, J. G., du Souich, P. (1995). Presystemic elimination of morphine in anesthetized rabbits: contribution of the intestine, liver, and lungs. Drug Metab Dispos 23:584–589.
   PubMed Web of Science ®Google Scholar
• Aiba, T., Takehara, Y., Okuno, M., Hashimoto, Y. (2003). Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res 20:745–748.
   PubMed Web of Science ®Google Scholar
• Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S., Teramura, T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308–316.
   PubMed Web of Science ®Google Scholar
• Arellano, C., Philibert, C., Vachoux, C., Woodley, J., Houin, G. (2007). The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J Pharm Pharmaceut Sci 10:26–36.
   PubMed Web of Science ®Google Scholar
• Bae, S. K., Chung, W. S., Kim, E. J., Rhee, J. K., Kwon, J. W., Kim, W. B., et al. (2004). Pharmacokinetics of DA-7867, a new oxazolidione, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother 48:659–662.
   PubMed Web of Science ®Google Scholar
• Bae, S. K., Yang, K. H., Aryal, D. K., Kim, Y. G., Lee, M. G. (2009). Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. J Pharm Sci 98:1587–1601.
   PubMed Web of Science ®Google Scholar
• Bernard, O., Guillemette, C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775–778.
   PubMed Web of Science ®Google Scholar
• Bowalgaha, K., Miners, J. O. (2001). The glucuronidation of mycophenolic acid by human liver, kidney, and jejunum microsomes. Br J Clin Pharmacol 52:605–609.
   PubMed Web of Science ®Google Scholar
• Boxenbaum, H. (1980). Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165–176.
   PubMedGoogle Scholar
• Brand, W., Boersma, M. G., Bik, H., Hoek-van den Hil, E. F., Vervoort, J., Barron, D., et al. (2010). Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 38:617–625.
   PubMed Web of Science ®Google Scholar
• Brand, W., van der Wel, P. A., Rein, M. J., Barron, D., Williamson, G., van Bladeren, P. J., et al. (2008). Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 36:1794–1802.
   PubMed Web of Science ®Google Scholar
• Carr, B., Norcross, R., Fang, Y., Lu, P., Rodrigues, A. D., Shou, M., Rushmore, T., et al. (2006). Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703–1712.
   PubMed Web of Science ®Google Scholar
• Chen, X., Yin, O. Q., Zuo, Z., Chow, M. S. (2005). Pharmacokinetics and modeling of quercetin and metabolites. Pharm Res 22:892–901.
   PubMed Web of Science ®Google Scholar
• Choi, Y. H., Kim, S. G., Lee, M. G. (2006). Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543–2552.
   PubMed Web of Science ®Google Scholar
• Crespy, V., Morand, C., Manach, C., Besson, C., Demigne, C., Remesy, C. (1999). Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol 277:G120–G126
   PubMed Web of Science ®Google Scholar
• Crowe, A., Bruelisauer, A., Duerr, L., Guntz, P., Lemaire, M. (1999). Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 27:627–632.
   PubMed Web of Science ®Google Scholar
• Cubitt, H. E., Houston, J. B., Galetin, A. (2009). Relative importance of intestinal and hepatic glucuronidation-Impact on the prediction of drug clearance. Pharm Res 26:1073–1083.
   PubMed Web of Science ®Google Scholar
• de Graaf, I. A., de Kanter, R., de Jager, M. H., Camacho, R., Langenkamp, E., van de Kerkhof, E. G., et al. (2006). Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 34;591–599.
   PubMed Web of Science ®Google Scholar
• de Kanter, R., Tuin, A., van de Kerkhof, E., Martignoni, M., Draaisma, A. L., de Jager, M. H., et al. (2005). A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies. J Pharmacol Toxicol Meth 51:65–72.
   PubMedGoogle Scholar
• Dean, B. J., Chang, S., Elipe, M. V., Xia, Y. Q., Braun, M., Soli, E., et al. (2007). Metabolism of MK-0524, a prostaglandin D2 Receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos 35:283–292.
   PubMed Web of Science ®Google Scholar
• Doherty MM, Pang KS. (2000). Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm Res 17:291–298.
   PubMed Web of Science ®Google Scholar
• Dubey, R. K., Singh, J. (1988). Localization and characterization of drug-metabolizing enzymes along the villus-crypt surface of the rat small intestine—II. Conjugases. Biochem Pharmacol 37:177–184.
   PubMed Web of Science ®Google Scholar
• Ducharme, M. P., Warbasse, L. H., Edwards, D. J. (1995). Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57:485–491.
   PubMed Web of Science ®Google Scholar
• Eeckhoudt, S. L., Horsmans, Y., Verbeeck, R. K. (2002). Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32:975–984.
   PubMed Web of Science ®Google Scholar
• Emoto, C., Yamazaki, H., Iketaki, H., Yamasaki, S., Satoh, T., Shimizu, R., et al. (2001). Cooperativity of α-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica 31:265–275.
   PubMed Web of Science ®Google Scholar
• Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M., Yokoi, T. (2000a). Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 30:943–953.
   PubMed Web of Science ®Google Scholar
• Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M., Yokoi, T. (2000b). Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica 30:971–982.
   PubMed Web of Science ®Google Scholar
• Fisher, M. B., Campanale, K., Ackermann, B. L., Vandenbranden, M., Wrighton, S. A. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560–566.
   PubMed Web of Science ®Google Scholar
• Fisher, M. B., Paine, M. F., Strelevitz, T. J., Wrighton, S. A. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273–297.
   PubMed Web of Science ®Google Scholar
• Fisher, M. B., Vandenbranden, M., Findlay, K., Burchell, B., Thummel, K. E., Hall, S. D., et al. (2000). Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727–739.
   PubMedGoogle Scholar
• Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., et al. (1997). Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–49.
   PubMed Web of Science ®Google Scholar
• Fraser, D. J., Feyereisen, R., Harlow, G. R., Halpert, J. R. (1997). Isolation, heterologous expression, and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283:1425–1432.
   PubMed Web of Science ®Google Scholar
• Fromm, M. F., Busse, D., Kroemer, H. K., Eichelbaum, M. (1996). Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796–801.
   PubMed Web of Science ®Google Scholar
• Fujiwara, R., Nakajima, M., Oda, S., Yamanaka, H., Ikushiro, S., Sakaki, T., et al. (2010). Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J Pharm Sci 99:442–454.
   PubMed Web of Science ®Google Scholar
• Fujiwara, R., Nakajima, M., Yamanaka, H., Nakamura, A., Katoh, M., Ikushiro, S., et al. (2007a). Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747–757.
   PubMed Web of Science ®Google Scholar
• Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M., Yokoi, T. (2007b). Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos 35:1782–1787.
   Google Scholar
• Galetin, A., Houston, J. B. (2006). Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220–1229.
   PubMed Web of Science ®Google Scholar
• Gertz, M., Davis, J. D., Harrison, A., Houston, J. B., Galetin, A. (2008). Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9;785–795.
   PubMed Web of Science ®Google Scholar
• Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S., et al. (2004). Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314–320.
   PubMed Web of Science ®Google Scholar
• Glaeser, H., Drescher, S., Hofmann, U., Heinkele, G., Somogyi, A. A., Eichelbaum, M., et al. (2004). Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther 76:230–238.
   PubMed Web of Science ®Google Scholar
• Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Herbert, M. F., Benet, L. Z. (1995). The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15–19.
   PubMed Web of Science ®Google Scholar
• Gong, Q. H., Cho, J. W., Huang, T., Potter, C., Gholami, N., Basu, N. K., et al. (2001). Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357–368.
   PubMedGoogle Scholar
• Gorski, J. C., Vannaprasaht, S., Hamman, M. A., Ambrosius, W. T., Bruce, M. A., Haehner-Daniels, B., et al. (2003). The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275–287.
   PubMed Web of Science ®Google Scholar
• Granvil, C. P., Yu, A. M., Elizondo, G., Akiyama, T. E., Cheung, C., Feigenbaum, L., et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548–558.
   PubMed Web of Science ®Google Scholar
• Gregory, P. A., Lewinsky, R. H., Gardner-Stephen, D. A., Mackenzie, P. I. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol App Pharmacol 199;354–363.
   PubMed Web of Science ®Google Scholar
• Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., Waxman, D. J. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–5060.
   PubMed Web of Science ®Google Scholar
• Gupta, S. K., Bakran, A., Johnson, R. W., Rowland, M. (1988). Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 25:401–402.
   PubMed Web of Science ®Google Scholar
• Gupta, M., Kovar, A., Meibohm, B. (2005). The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987–1003.
   PubMed Web of Science ®Google Scholar
• Hanada, K., Ikemi, Y., Kukita, K., Mihara, K., Ogata, H. (2008). Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats. Drug Metab Dispos 36:2037–2042.
   PubMed Web of Science ®Google Scholar
• Hashimoto, Y., Sasa, H., Shimomura, M., Inui, K. (1998). Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 15:1609–1613.
   PubMed Web of Science ®Google Scholar
• Hebert, M. F., Roberts, J. P., Prueksaritanont, T., Benet, L. Z. (1992). Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453–457.
   PubMed Web of Science ®Google Scholar
• Higashikawa, F., Murakami, T., Kaneda, T., Kato, A., Takano, M. (1998). Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51:67–72.
   Web of Science ®Google Scholar
• Hirunpanich, V., Katagi, J., Sethabouppha, B., Sato, H. (2006). Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. Drug Metab Dispos 34:305–310.
   PubMed Web of Science ®Google Scholar
• Hirunpanich, V., Murakoso, K., Sato, H. (2008). Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. Int J Pharm 351:133–143.
   PubMedGoogle Scholar
• Ho, Y. F., Huang, D. K., Hsueh, W. C., Lai, M. Y., Yu, H. Y., Tsai, T. H. (2009). Effect of St. John’s wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. Life Sci 85:296–302.
   PubMed Web of Science ®Google Scholar
• Holtbecker, N., Fromm, M. F., Kroemer, H. K., Ohnhaus, E. E., Heidemann, H. (1996). The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121–1123.
   PubMed Web of Science ®Google Scholar
• Houston, J. B., Kenworthy, K. E. (2000). In vitro–in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246–254.
   PubMed Web of Science ®Google Scholar
• Ikemura, K., Urano, K., Matsuda, H., Mizutani, H., Iwamoto, T., Okuda, M. (2009). Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells. J Pharmacol Exp Ther 328:249–255.
   PubMed Web of Science ®Google Scholar
• Itääho, K., Court, M. H., Uutela, P., Kostiainen, R., Radominska-Pandya, A., Finel, M. (2009). Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferease 1A10. Drug Metab Dispos 37:768–775.
   PubMed Web of Science ®Google Scholar
• Iwamoto, K., Klaassen, C. D. (1977). First-pass effect of morphine in rats. J Pharmacol Exp Ther 200:236–244.
   PubMed Web of Science ®Google Scholar
• Iwao, T., Inoue, K., Hayashi, Y., Yuasa, H., Watanabe, J. (2002). Metabolic extraction of nifedipine during absorption from the rat small intestine. Drug Metab Pharmacokinet 17:546–553.
   PubMedGoogle Scholar
• Iwasaki, K., Murayama, N., Koizumi, R., Uno, Y., Yamazaki, H. (2010). Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab Pharmacokinet 25:388–391.
   PubMed Web of Science ®Google Scholar
• Iwasaki, K., Uno, Y. (2009). Cynomolgus monkey CYPs: comparison with human CYPs. Xenobiotica 39:578–581.
   PubMed Web of Science ®Google Scholar
• Jäger, W., Correia, M. A., Bornheim, L. M., Mahnke, A., Hanstein, W. G., Xue, L., et al. (1999). Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab Dispos 27:1505–1511.
   PubMed Web of Science ®Google Scholar
• Jeong, E. J., Liu, Y., Lin, H., Hu, M. (2005). Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785–794.
   PubMed Web of Science ®Google Scholar
• Jetter, A., Kinzig-Schippers, M., Walchner-Bonjean, M., Hering, U., Bulitta, J., Schreiner, P., et al. (2002). Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 71:21–29.
   PubMed Web of Science ®Google Scholar
• Jin, M., Shimada, T., Yokogawa, K., Nomura, M., Kato, Y., Tsuji, A., et al. (2006). Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int J Pharm 309:81–86.
   PubMed Web of Science ®Google Scholar
• Kaji, H., Kume, T. (2005). Regioselective glucuronidation of denopamine: marked species differences and identification of human UDP-glucuronosyltransferase isoform. Drug Metab Dispos 33:403–412.
   PubMed Web of Science ®Google Scholar
• Kanazu, T., Okamura, N., Yamaguchi, Y., Baba, T., Koike, M. (2005). Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 35:305–317.
   PubMed Web of Science ®Google Scholar
• Kanazu, T., Yamaguchi, Y., Okamura, N., Baba, T., Koike, M. (2004). Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391–402.
   PubMed Web of Science ®Google Scholar
• Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Nizuno, N., et al. (2003). The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein. Quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365–372.
   PubMedGoogle Scholar
• Kato, R., Yuasa, H., Inoue, K., Iwao, T., Tanaka, K., Ooi, K., et al. (2007). Effect of lactobacillus casei on the absorption of nifedipine from rat small intestine. Drug Metab Pharmacokinet 22:96–102.
   PubMed Web of Science ®Google Scholar
• Kemp, D. C., Fan, P. W., Stevens, J. C. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700.
   PubMed Web of Science ®Google Scholar
• Kolars, J. C., Awni, W. M., Merion, R. M., Watkins, P. B. (1991). First-pass metabolism of cyclosporine by the gut. Lancet 14:1488–1490.
   Google Scholar
• Komura, H., Iwaki, M. (2008). Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775–1800.
   PubMed Web of Science ®Google Scholar
• Komura, H., Yasuda, M., Yoshida, N. H., Sugiyama, Y. (2002). Species difference in nisoldipine oxidation activity in the small intestine. Drug Metab Pharmacokinet 17:427–436.
   PubMedGoogle Scholar
• Kotegawa, T., Laurijssens, B. E., von Moltke, L. L., Cotreau, M. M., Perloff, M. D., Venkatakrishnan, K., et al. (2002). In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconzole and midazolam in the rat. J Pharmacol Exp Ther 302:1228–1237.
   PubMed Web of Science ®Google Scholar
• Kuroha, M., Kayaba, H., Kishimoto, S., Khalil, W. F., Shimoda, M., Kokue, E. (2002). Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91:868–873.
   PubMed Web of Science ®Google Scholar
• Kuroiwa, Y., Yoshida, H., Ohshima, T., Shinohara, T., Ohguma, A., Kazuki, Y., et al. (2002). The use of chromosome-based vectors for animal transgenesis. Gene Ther 9:708–712.
   PubMed Web of Science ®Google Scholar
• Kurosawa, S., Uchida, S., Ito, Y., Yamada, S. (2009). Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats. Xenobiotica 39:162–170.
   PubMed Web of Science ®Google Scholar
• Kuze, J., Mutoh, T., Takenaka, T., Morisaki, K., Nakura, H., Hanioka, N., et al. (2009). Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 39:871–880.
   PubMed Web of Science ®Google Scholar
• Kyokawa, Y., Nishibe, Y., Wakabayashi, M., Harauchi, T., Maruyama, T., Baba, T., et al. (2001). Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. Chem Biol Interact 134:291–305.
   PubMed Web of Science ®Google Scholar
• Lampen, A., Christians, U., Bader, A., Hackbarth, I., Sewing, K. F. (1996a). Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 52:159–168.
   PubMed Web of Science ®Google Scholar
• Lampen, A., Christians, U., Gonschior, A. K., Bader, A., Hackbarth, I., von Engelhardt, W., et al. (1996b). Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730–1734.
   PubMed Web of Science ®Google Scholar
• Lampen, A., Zhang, Y., Hackbarth, I., Benet, L. Z., Sewing, K. F., Christians, U. (1998). Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285:1104–1112.
   PubMed Web of Science ®Google Scholar
• Lee, J. I., Chaves-Gnecco, D., Amico, J. A., Kroboth, P. D., Wilson, J. W., Frye, R. F. (2002). Application of semisimultanenous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72:718–728.
   PubMed Web of Science ®Google Scholar
• Lee, Y. H., Perry, B. A., Lee, H. S., Kunta, J. R., Sutyak, J. P., Sinko, P. J. (2001). Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. Pharm Res 18:1721–1728.
   PubMed Web of Science ®Google Scholar
• Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., et al. (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–172.
   PubMed Web of Science ®Google Scholar
• Lindstrom, T. D., Whitaker, N. G., Whitaker, G. W. (1984). Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs, and monkeys. Xenobiotica 14:841–847.
   PubMed Web of Science ®Google Scholar
• Liu, Z., Hu, M. (2007). Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 3:389–406.
   PubMed Web of Science ®Google Scholar
• Loureiro, A. I., Bonifácio, M. J., Fernandes-Lopes, C., Almeida, L., Wright, L. C., Soares-Da-Silva, P. (2006). Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos 34:1856–1862.
   PubMed Web of Science ®Google Scholar
• Lown, K. S., Ghosh, M., Watkins, P. B. (1998). Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 26:185–187.
   PubMed Web of Science ®Google Scholar
• Mackenzie, P. I., Bock, K. W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–685.
   PubMed Web of Science ®Google Scholar
• Martignoni, M., Groothuis, G., de Kanter, R. (2006). Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 34:1047–1054.
   PubMed Web of Science ®Google Scholar
• Masica, A. L., Mayo, G., Wilkinson, G. R. (2004). In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76:341–349.
   PubMed Web of Science ®Google Scholar
• Matsubara, T., Kim, H. J., Miyata, M., Shimada, M., Nagata, K., Yamazoe, Y. (2004). Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 309:1282–1290.
   PubMed Web of Science ®Google Scholar
• Mazoit, J. X., Sandouk, P., Scherrmann, J. M., Roche, A. (1990). Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 48:613–618.
   PubMed Web of Science ®Google Scholar
• Mealey, K. L., Jabbes, M., Spencer, E., Akey, J. M. (2008). Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38:1305–1312.
   PubMed Web of Science ®Google Scholar
• Miles, K. K., Kessler, F. K., Smith, P. C., Ritter, J. K. (2006). Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos 34:1632–1639.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Mackenzie, P. I., Knights, K. M. (2010). The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196–208.
   PubMed Web of Science ®Google Scholar
• Mistry, M., Houston, J. B. (1987). Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 15:710–717.
   PubMed Web of Science ®Google Scholar
• Mizuma, T. (2009). Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140–141.
   PubMed Web of Science ®Google Scholar
• Muirhead, G. J., Rance, D. J., Walker, D. K., Wastall, P. (2002). Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53: 13–S20S
   Web of Science ®Google Scholar
• Murai, T., Samata, N., Iwabuchi, H., Ikeda, T. (2006). Human UDP-glucuronosyltransferase, UGT1A8, glucruonidates dihydrotestosterone to a monoglucuronide and further to a structurally novel diglucuronide. Drug Metab Dispos 34:1102–1108.
   PubMed Web of Science ®Google Scholar
• Murakami, T., Nakanishi, M., Yoshimori, T., Okamura, N., Norikura, R., Mizojiri, K. (2003). Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18:252–260.
   PubMedGoogle Scholar
• Muzeeb, S., Basha, S. J., Shashikumar, D., Mullangi, R., Srinivas, N. R. (2006). Glucuronidation of DRF-6574, hydroxyl metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes, and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3, and 1A8. Eur J Drug Metab Pharmacokinet 31:299–309.
   PubMed Web of Science ®Google Scholar
• Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–1464.
   PubMed Web of Science ®Google Scholar
• Nakanishi, Y., Matsushita, A., Matsuno, K., Iwasaki, K., Utoh, M., Nakamura, C., et al. (2010). Regional distribution of cytochrome P450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab Pharmacokinet 25:290–297.
   PubMed Web of Science ®Google Scholar
• Nishikawa, M., Ariyoshi, N., Kotani, A., Ishii, I., Nakamura, H., Nakasa, H., et al. (2004). Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 19:280–289.
   PubMedGoogle Scholar
• Nishimura, T., Amano, N., Kubo, Y., Ono, M., Kato, Y., Fujita, H., et al. (2007). Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 35:1275–1284.
   PubMed Web of Science ®Google Scholar
• Nishimura, M., Koeda, A., Morikawa, H., Satoh, T., Narimatsu, S., Naito, S. (2009). Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab Pharmacokinet 24:139–144.
   PubMed Web of Science ®Google Scholar
• Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S., Satoh, T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369–375.
   PubMed Web of Science ®Google Scholar
• Nishimuta, H., Sato, K., Mizuki, Y., Yabuki, M., Komuro, S. (2010). Prediction of the intestinal first-pass metabolism of CYP3 substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38:1967–1975.
   PubMed Web of Science ®Google Scholar
• Ogasawara, A., Kume, T., Kazama, E. (2007). Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410–418.
   PubMed Web of Science ®Google Scholar
• Ohno, S., Nakajin, S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40.
   PubMed Web of Science ®Google Scholar
• Ohtsuka, T., Yoshikawa, T., Kozakai, K., Tsuneto, Y., Uno, Y., Utho, M., et al. (2010). Alprazolam as an in vivo probe for studing induction of CYP3A in cynomolgus monkeys. Drug Metab Dispos 38:1806–1813.
   PubMed Web of Science ®Google Scholar
• Osborne, R., Joel, S., Trew, D., Slevin, M. (1990). Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Cline Pharmacol Ther 47:12–19.
   PubMed Web of Science ®Google Scholar
• Oshimura, M., Katoh, M. (2008). Transfer of human artificial chromosome vectors into stem cells. Reprod Biomed Online 16:57–69.
   PubMed Web of Science ®Google Scholar
• Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., Zeldin, D. C. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–886.
   PubMed Web of Science ®Google Scholar
• Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., et al. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552–1562.
   PubMed Web of Science ®Google Scholar
• Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., et al. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14–24.
   PubMed Web of Science ®Google Scholar
• Patel, J. P., Korashy, H. M., EI-Kadi, A. O., Brocks, D. R. (2010). Effect of bile and lipids on the stereoselective metabolism of halofantrine by rat everted-intestinal sacs. Chirality 22:275–283.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., Vyas, K. P. (1996). Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24:634–642.
   PubMed Web of Science ®Google Scholar
• Ritter, J. K. (2007). Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Exp Opin Drug Toxicol 3:93–107.
   PubMed Web of Science ®Google Scholar
• Sakuda, S., Akabane, T., Teramura, T. (2006). Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 36:331–340.
   PubMed Web of Science ®Google Scholar
• Sandström, R., Knutson, T. W., Knutson, L., Jansson, B., Lennernäs, H. (1999). The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 48:180–189.
   PubMed Web of Science ®Google Scholar
• Schmider, J., Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Shader, R. I. (1995). N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 275:592–597.
   PubMed Web of Science ®Google Scholar
• Shelby, M. K., Cherrington, N. J., Vansell, N. R., Klaassen, C. D. (2003). Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326–333.
   PubMed Web of Science ®Google Scholar
• Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F. P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
   PubMed Web of Science ®Google Scholar
• Shin, H. S., Bae, S. K., Lee, M. G. (2006). Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharm 320:64–70.
   PubMed Web of Science ®Google Scholar
• Shiratani, H., Katoh, M., Nakajima, M., Yokoi, T. (2008). Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745–1752.
   PubMed Web of Science ®Google Scholar
• Silberberg, M., Morand, C., Mathevon, T., Besson, C., Manach, C., Scalbert, A., et al. (2006). The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 45:88–96.
   PubMed Web of Science ®Google Scholar
• Soars, M. G., Burchell, B., Riley, R. J. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382–390.
   PubMed Web of Science ®Google Scholar
• Strassburg, C. P., Kneip, S., Topp, J., Obermayer-Straub, P., Barut, A., Tukey, R. H., et al. (2000). Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164–36171.
   PubMed Web of Science ®Google Scholar
• Strelevitz, T. J., Foti, R. S., Fisher, M. B. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334–1341.
   PubMed Web of Science ®Google Scholar
• Tachibana, T., Kato, M., Takano, J., Sugiyama, Y. (2010). Predicting drug-drug interactions involving the inhibition of intestinal CYP3A and P-glycoprotein. Curr Drug Metab 11:762–777.
   PubMed Web of Science ®Google Scholar
• Takahashi, M., Washio, T., Suzuki, N., Igeta, K, Yamashita, S. (2009). The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343–4353.
   PubMed Web of Science ®Google Scholar
• Takanaga, H., Ohnishi, A., Murakami, H., Matsuo, H., Higuchi, S., Urae, A., et al. (2000). Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 67:201–214.
   PubMed Web of Science ®Google Scholar
• Takara, K., Ohnishi, N., Horibe, S., Yokoyama, T. (2003). Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab Dispos 31:1235–1239.
   PubMed Web of Science ®Google Scholar
• Takemoto, K., Yamazaki, H., Tanaka, Y., Nakajima, M., Yokoi, T. (2003). Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransfereases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica 33:43–55.
   PubMed Web of Science ®Google Scholar
• Tang, L., Singh, R., Liu, Z., Hu, M. (2009). Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol Pharm 6:1466–1482.
   PubMed Web of Science ®Google Scholar
• Thummel, K. E., O’Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., et al. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491–502.
   PubMed Web of Science ®Google Scholar
• Tsunoda, S. M., Velez, R. L., von Moltke, L. L., Greenblatt, D. J. (1999). Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461–471.
   PubMed Web of Science ®Google Scholar
• Tsuruta, S., Nakamura, K., Arimori, K., Nakano, M. (1997). Inhibition of nifedipine metabolism in dogs by erythromycin: difference between the gut wall and the liver. J Pharm Pharmacol 49:1205–1210.
   PubMed Web of Science ®Google Scholar
• Uno, Y., Matsushita, A., Osada, N., Uehara, S., Kohara, S., Nagata, R., et al. (2010). Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos 38:209–214.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof, E. G., Ungell, A. L., Sjöberg, Å,. K., de Jager, M. H., Hilgendorf, C., de Graaf, I. A., et al. (2006). Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Metab Dispos 34:1893–1902.
   PubMed Web of Science ®Google Scholar
• van Herwaarden, A. E., van Waterschoot, R. A., Schinkel, A. H. (2009). How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol Sci 30:223–227.
   PubMed Web of Science ®Google Scholar
• van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M., van Waterschoot, R. A., Smit, J. W., et al. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583–3592.
   PubMed Web of Science ®Google Scholar
• van Waterschoot, R. A., Rooswinkel, R. W., Sparidans, R. W., van Herwaarden, A. E., Beijnen, J. H., Schinke, A. H. (2009). Inhibition and simulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305–2313.
   PubMed Web of Science ®Google Scholar
• von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., Kivistö, K. T. (2004). Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75:172–183.
   PubMed Web of Science ®Google Scholar
• von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., et al. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 70:217–227.
   PubMed Web of Science ®Google Scholar
• Wakui, Y., Yanagisawa, E., Ishibashi, E., Matsuzaki, Y., Takeda, S., Sasaki, H., et al. (1992). Determination of baicalin and baicalein in rat plasma by high-performance liquid chromatography wih electrochemical detection. J Chromatogr 575:131–136.
   PubMed Web of Science ®Google Scholar
• Watanabe, Y., Nakajima, M., Yokoi, T. (2002). Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462–1469.
   PubMed Web of Science ®Google Scholar
• Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., Guzelian, P. S. (1987). Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029–1036.
   PubMed Web of Science ®Google Scholar
• Wilkinson, G. R. (2005). Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221.
   PubMed Web of Science ®Google Scholar
• Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab Dispos 32:1201–1208.
   PubMed Web of Science ®Google Scholar
• Wojnowski, L., Kamdem, L. K. (2006). Clinical implications of CYP3A polymorphisms. Exp Opin Drug Metab Toxicol 2:171–182.
   PubMed Web of Science ®Google Scholar
• Yamanaka, H., Nakajima, M., Katoh, M., Yokoi, T. (2007). Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 35:1642–1648.
   PubMed Web of Science ®Google Scholar
• Yang, J., Tucker, G. T., Rostami-Hodjegan, A. (2004). Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 76:391.
   PubMed Web of Science ®Google Scholar
• Yokomasu, A., Yano, I., Sato, E., Masuda, S., Katsura, T., Inui, K. (2008). Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everlimus in rats. Drug Metab Pharmacokinet 23:469–475.
   PubMed Web of Science ®Google Scholar
• Yoshisue, K., Nagayama, S., Shindo, T., Kawaguchi, Y. (2001). Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther 297:1166–1175.
   PubMed Web of Science ®Google Scholar
• Zhang, Q. Y., Dunbar, D., Kaminsky, L. S. (2003). Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346–1351.
   PubMed Web of Science ®Google Scholar
• Zhang, Q. Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., Kaminsky, L. S. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804–809.
   PubMed Web of Science ®Google Scholar
• Zhang, Q. Y., Fang, C., Zhang, J., Dunbar, D., Kaminsky, L., Ding, X. (2009b). An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal cytochrome P450s in first-pass clearance of oral nefedipine. Drug Metab Dispos 37:651–657.
   PubMed Web of Science ®Google Scholar
• Zhang, Q. Y., Kaminsky, L. S., Dunbar, D., Zhang, J., Ding, X. (2007). Role of small intestinal cytochromes P450 in the bioavailability of oral nifedipine. Drug Metab Dispos 35:1617–1623.
   PubMed Web of Science ®Google Scholar
• Zhang, L., Lin, G., Chang, Q., Zuo, Z. (2005). Role of intestinal first-pass metabolism of baicalein in its absorption process. Pharm Res 22:1050–1058.
   PubMed Web of Science ®Google Scholar
• Zhang, L., Lin, G., Zuo, Z. (2006). Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharm Res 24:81–89.
   PubMed Web of Science ®Google Scholar
• Zhang, QY, Wikoff, J, Dunbar, D, Kaminsky, L. (1996). Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab Dispos 24:322–328.
   PubMed Web of Science ®Google Scholar
• Zhang, H., Wu, X., Naraharisetti, S. B., Chung, F., Whittington, D., Mirfazaclian, A., et al. (2009a). Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina. J Pharmacol Exp Ther 330:586–595.
   PubMed Web of Science ®Google Scholar
• Zhu, Y., D’Agostino, J., Zhang, Q.-Y. (2011). Role of intestinal cytochrome P450 in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos 39;939–943.
   PubMed Web of Science ®Google Scholar
• Zuber, R., Anzenbacherová, E., Anzenbacher, P. (2002). Cytochrome P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–198.
   PubMed Web of Science ®Google Scholar